Related references
Note: Only part of the references are listed.Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis
G. Fabiano et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2023)
The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis
Anusha Ponduri et al.
LARYNGOSCOPE (2023)
Updates on HPV Vaccination
Ojone Illah et al.
DIAGNOSTICS (2023)
Human Papillomavirus-associated Anal Cancer Incidence and Burden Among US Men, According to Sexual Orientation, Human Immunodeficiency Virus (HIV) Status, and Age
Ashish A. Deshmukh et al.
CLINICAL INFECTIOUS DISEASES (2023)
Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis
Ashish A. Deshmukh et al.
INTERNATIONAL JOURNAL OF CANCER (2023)
Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States
Patrick A. Clay et al.
VACCINE (2023)
Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy
Peter Goon et al.
NPJ VACCINES (2023)
Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally
J. Andrew Dykens et al.
FRONTIERS IN PUBLIC HEALTH (2023)
Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study
Cecilia Acuti Martellucci et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)
Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening
Talia Malagon et al.
CLINICAL INFECTIOUS DISEASES (2022)
Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania's national HPV vaccine introduction
Anyie J. Li et al.
VACCINE (2022)
Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa
Ahmadaye Ibrahim Khalil et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Evaluating Risk-Stratified HPV Catch-up Vaccination Strategies: Should We Go beyond Age 26?
Fan Wang et al.
MEDICAL DECISION MAKING (2022)
HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis
Violante Di Donato et al.
VACCINES (2022)
Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis
Dina Overgaard Eriksen et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2022)
Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer
Rebecca B. Perkins et al.
ANNALS OF INTERNAL MEDICINE (2022)
The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot
Matejka Rebolj et al.
BRITISH JOURNAL OF CANCER (2022)
Possible Reactivation of Latent Anal Human Papillomavirus Associated with Markers of Immune Dysfunction in Gay and Bisexual Men
I. Mary Poynten et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)
Anal Cancer Screening and Prevention: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Guidelines
Luis F. Barroso et al.
CLINICAL INFECTIOUS DISEASES (2022)
Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis A Nonrandomized Clinical Trial
Jana Smahelova et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2022)
Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
Juan J. Hernandez-Aguado et al.
VACCINES (2022)
Viral Pathogens in Oesophageal and Gastric Cancer
Kishen Rajendra et al.
PATHOGENS (2022)
Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy
Sile Li et al.
TUMOUR VIRUS RESEARCH (2022)
Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies
Serra Lem Asangbeh-Kerman et al.
BMC PUBLIC HEALTH (2022)
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
J. M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State
Ayazhan Akhatova et al.
VACCINES (2022)
Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis
Konstantinos S. Kechagias et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
The HIV Epidemic in South Africa: Key Findings from 2017 National Population-Based Survey
Khangelani Zuma et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands
Joost J. M. Simons et al.
PREVENTIVE MEDICINE REPORTS (2022)
Human papillomavirus-related neoplasia of the ocular adnexa
Ingvild Margrethe Sellaeg Ramberg
ACTA OPHTHALMOLOGICA (2022)
Immunogenicity and safety of two novel human papillomavirus 4-and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial
Yajun Shu et al.
VACCINE (2022)
Increased prevalence of human papillomavirus in fresh tissue from penile cancers compared to non-malignant penile samples: a case-control study
Sinja Kristiansen et al.
BMC CANCER (2022)
Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma
Edoardo Colzani et al.
EUROSURVEILLANCE (2021)
Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States
Vincent Daniels et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States
Elissa Meites et al.
CLINICAL INFECTIOUS DISEASES (2021)
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials
Filipe Colaro Mariz et al.
LANCET INFECTIOUS DISEASES (2021)
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
Partha Basu et al.
LANCET ONCOLOGY (2021)
Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis
Lafi Aldakak et al.
VACCINE (2021)
Misclassifications in human papillomavirus databases
Laila Sara Arroyo Muhr et al.
VIROLOGY (2021)
Estimates of the global burden of cervical cancer associated with HIV
Dominik Stelzle et al.
LANCET GLOBAL HEALTH (2021)
Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
Giovanni Diana et al.
ORAL ONCOLOGY (2021)
Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years
Shujuan Lin et al.
CANCER (2021)
Human Papillomavirus-Associated Head and Neck Cancer
Juan C. Nogues et al.
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE (2021)
Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from
Eric P. F. Chow et al.
LANCET INFECTIOUS DISEASES (2021)
Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial
Penelope Gray et al.
PLOS MEDICINE (2021)
Genotype Distribution Change After Human Papillomavirus Vaccination in Two Autonomous Communities in Spain
Javier Freire-Salinas et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
Juvenile-Onset Recurrent Respiratory Papillomatosis in the United States, Epidemiology and HPV Types-2015-2020
Raiza Amiling et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)
Human Papillomavirus Vaccination After COVID-19
Zheng Quan Toh et al.
JNCI CANCER SPECTRUM (2021)
World Health Organization call for action to eliminate cervical cancer globally
Murat Gultekin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Nonavalent human papillomavirus vaccination as alternative treatment for genital warts
Simon Bossart et al.
DERMATOLOGIC THERAPY (2020)
Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women
Michael J. Silverberg et al.
VACCINE (2020)
Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines
Sabrina H. Tsang et al.
VACCINE (2020)
Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females
Asvini K. Subasinghe et al.
SEXUAL HEALTH (2020)
IPVS statement on Temporary HPV vaccine shortage: Implications globally to achieve equity
Suzanne M. Garland et al.
PAPILLOMAVIRUS RESEARCH (2020)
Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort
Hanna Artemchuk et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus-infected Women: A Systematic Review and Meta-analysis of Treatment Failure
Pierre Debeaudrap et al.
CLINICAL INFECTIOUS DISEASES (2019)
ICTV Virus Taxonomy Profile: Togaviridae
Rubing Chen et al.
JOURNAL OF GENERAL VIROLOGY (2018)
Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis
Chunqing Lin et al.
LANCET INFECTIOUS DISEASES (2018)
HPV vaccines - A review of the first decade
Diane M. Harper et al.
GYNECOLOGIC ONCOLOGY (2017)
Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine
Zhigang Zhang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study
Tulio de Oliveira et al.
LANCET HIV (2017)
Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies
Amy Sarah Ginsburg et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa
Gary M. Clifford et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer
Zhen Gooi et al.
LARYNGOSCOPE (2016)
A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil
Jessica L. Castilho et al.
BMC CANCER (2015)
Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status
Zizipho Z. A. Mbulawa et al.
BMC INFECTIOUS DISEASES (2015)
A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer
Donna M. Graham et al.
CANCER (2015)
Unique Human Papillomavirus-Type Distribution in South African Women With Invasive Cervical Cancer and the Effect of Human Immunodeficiency Virus Infection
Matthys Cornelis van Aardt et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2015)
Cancer of the cervix: Early detection and cost-effective solutions
Lynette Denny et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2015)
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2015)
Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa
Lynette Denny et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
High-risk human papillomavirus viral load and persistence among heterosexual HIV-negative and HIV-positive men
Mary K. Grabowski et al.
SEXUALLY TRANSMITTED INFECTIONS (2014)
Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination
Jeanne M. Pimenta et al.
BMC CANCER (2013)
Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial
Mahboobeh Safaeian et al.
CANCER PREVENTION RESEARCH (2013)
Significant Decrease in the Incidence of Genital Warts in Young Danish Women After Implementation of a National Human Papillomavirus Vaccination Program
Louise Baandrup et al.
SEXUALLY TRANSMITTED DISEASES (2013)
Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis
Pascale Lissouba et al.
SEXUALLY TRANSMITTED INFECTIONS (2013)
Global Burden of Human Papillomavirus and Related Diseases
David Forman et al.
VACCINE (2012)
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Hans-Ulrich Bernard et al.
VIROLOGY (2010)
Genital Human Papillomavirus Prevalence and Human Papillomavirus Concordance in Heterosexual Couples Are Positively Associated with Human Immunodeficiency Virus Coinfection
Zizipho Z. A. Mbulawa et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
A review of human carcinogens-Part B: biological agents
Veronique Bouvard et al.
LANCET ONCOLOGY (2009)
Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in south Africa
Dianne J. Marais et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
John T. Schiller et al.
VACCINE (2008)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A. Joura et al.
LANCET (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The global health burden of infection -associated cancers in the year 2002
Donald Maxwell Parkin
INTERNATIONAL JOURNAL OF CANCER (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Human papillomavirus types in invasive cervical cancer worldwide:: a meta-analysis
GM Clifford et al.
BRITISH JOURNAL OF CANCER (2003)